Orthofix launches OsteoCove bioactive synthetic graft
October 12, 2023
Orthofix today announced it received FDA 510(k) clearance for its OsteoCove bioactive synthetic graft.
Orthofix today announced it received FDA 510(k) clearance for its OsteoCove bioactive synthetic graft.
The expanded indication positions Boston Scientific to challenge Abbott, Medtronic and Nevro for the emerging opportunity in spinal cord stimulation to treat the condition.